Jose M Moraleda
Overview
Explore the profile of Jose M Moraleda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
1784
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zugasti I, Tormo-Ratera M, Oliver-Caldes A, Soler-Perromat J, Gonzalez-Calle V, Moreno D, et al.
Blood Adv
. 2024 Nov;
9(3):571-582.
PMID: 39602341
Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in...
2.
Poveda-Garcia A, Ruiz E, Moreno M, Espanol I, Sanchez-Salinas A, Garcia-Hernandez A, et al.
Bone Marrow Transplant
. 2024 Aug;
59(11):1625-1627.
PMID: 39187602
No abstract available.
3.
Gil-Chinchilla J, Zapata A, Moraleda J, Garcia-Bernal D
Biomolecules
. 2024 Jul;
14(7).
PMID: 39062449
Mesenchymal stem/stromal cells (MSCs) are one of the most widely used cell types in advanced therapies due to their therapeutic potential in the regulation of tissue repair and homeostasis, and...
4.
Beltran A, Sanchez-Villalobos M, Salido E, Alguero C, Campos E, Perez-Oliva A, et al.
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062184
Hereditary spherocytosis (HS) is a membranopathy that impacts the vertical junctions between the cytoskeleton and the plasma membrane of erythrocytes. The gold standard method for diagnosing it is osmotic gradient...
5.
Mo C, Richardson E, Calabretta E, Corrado F, Kocoglu M, Baron R, et al.
Blood Rev
. 2024 Jun;
66:101218.
PMID: 38852017
Patients with multiple myeloma (MM) were among the groups impacted more severely by the COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality. MM and COVID-19, plus post-acute...
6.
Gil-Chinchilla J, Bueno C, Martinez C, Ferrandez-Murtula A, Garcia-Hernandez A, Blanquer M, et al.
Front Immunol
. 2024 Apr;
15:1385691.
PMID: 38605955
Mesenchymal stem/stromal cells (MSCs) are being increasingly used in cell-based therapies due to their broad anti-inflammatory and immunomodulatory properties. Intravascularly-administered MSCs do not efficiently migrate to sites of inflammation/immunopathology, but...
7.
8.
Oliver-Caldes A, Espanol-Rego M, Zabaleta A, Gonzalez-Calle V, Navarro-Velazquez S, Inoges S, et al.
Clin Cancer Res
. 2024 Mar;
30(10):2085-2096.
PMID: 38466644
Purpose: B-cell maturation antigen (BCMA)-chimeric antigen receptor T-cells (CART) improve results obtained with conventional therapy in the treatment of relapsed/refractory multiple myeloma. However, the high demand and expensive costs associated...
9.
Bueno C, Garcia-Bernal D, Martinez S, Blanquer M, Moraleda J
Stem Cell Res Ther
. 2024 Feb;
15(1):32.
PMID: 38321563
Background: The neuronal transdifferentiation of adult bone marrow cells (BMCs) is still considered an artifact based on an alternative explanation of experimental results supporting this phenomenon obtained over decades. However,...
10.
Tilmont R, Yakoub-Agha I, Eikema D, Zinger N, Haenel M, Schaap N, et al.
Bone Marrow Transplant
. 2023 Aug;
58(11):1182-1188.
PMID: 37543712
In the setting of a first relapse of multiple myeloma (MM), a second autologous stem cell transplant (ASCT) following carfilzomib-lenalidomide-dexamethasone (KRd) is an option, although there is scarce data concerning...